GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Total Assets

NovMetaPharma Co (XKRX:229500) Total Assets : ₩4,648.53 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Total Assets?

NovMetaPharma Co's Total Assets for the quarter that ended in Dec. 2024 was ₩4,648.53 Mil.

During the past 12 months, NovMetaPharma Co's average Total Assets Growth Rate was -6.10% per year. During the past 3 years, the average Total Assets Growth Rate was 0.10% per year. During the past 5 years, the average Total Assets Growth Rate was 10.50% per year.

During the past 10 years, NovMetaPharma Co's highest 3-Year average Total Assets Growth Rate was 20.10%. The lowest was -8.00%. And the median was 10.20%.

Total Assets is connected with ROA %. NovMetaPharma Co's annualized ROA % for the quarter that ended in Dec. 2024 was -80.44%. Total Assets is also linked to Revenue through Asset Turnover. NovMetaPharma Co's Asset Turnover for the quarter that ended in Dec. 2024 was 0.01.

NovMetaPharma Co Total Assets Historical Data

The historical data trend for NovMetaPharma Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Total Assets Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,077.94 8,348.22 3,741.97 9,285.84 4,648.53

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,077.94 8,348.22 3,741.97 9,285.84 4,648.53

NovMetaPharma Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

NovMetaPharma Co's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=1756.588+2891.939
=4,648.53

NovMetaPharma Co's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=1756.588+2891.939
=4,648.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovMetaPharma Co  (XKRX:229500) Total Assets Explanation

Total Assets is connected with ROA %.

NovMetaPharma Co's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Dec. 2024 ))/ count )
=-5604.65/( (9285.836+4648.527)/ 2 )
=-5604.65/6967.1815
=-80.44 %

Note: The Net Income data used here is one times the annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

NovMetaPharma Co's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Dec. 2024 ))/ count )
=45.315/( (9285.836+4648.527)/ 2 )
=45.315/6967.1815
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

NovMetaPharma Co Total Assets Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Total Assets
Comparable Companies
XKRX:330350 XKRX:061250 XKRX:002210 XKRX:067290 XKRX:004310 XKRX:142280 XKRX:072020 XKRX:183490 XKRX:002720 XKRX:041910 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
Website
http://www.novmeta.com
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines